Psoriatic Disease

SCOTTSDALE, Ariz. — Interleukin-17 targeting, a tyrosine kinase 2 inhibitor and the “nanobody revolution” represent a promising new frontier for psoriatic arthritis, according to a speaker here.

Guselkumab demonstrates consistent pharmacological effects across both patients naïve to biologics and those with an inadequate response to TNF inhibitors, according data published in Arthritis & Rheumatology.

An initiative to switch clinically stable patients from Remicade to a biosimilar significantly increased biosimilar use in rheumatology and gastroenterology clinics within the University of North Carolina health system, according to data.

Patients reported low overall satisfaction with New Zealand’s mandatory nationwide transition to an adalimumab biosimilar, though most said they are still taking it and appreciated its less-painful injections, according to a study.

Among patients with psoriatic arthritis treated with guselkumab, early joint improvement by week 8 predicts lower radiographic progression rates through 2 years, according to data published in Clinical Rheumatology.

Patients receiving the adalimumab biosimilar SB5 demonstrated high persistence, consistent effectiveness and no new safety signals through 48 weeks, according to data published in BioDrugs.

SAN DIEGO — The likelihood of opioid use among patients with autoimmune rheumatic disease has decreased annually by 15% since 2014, according to data presented at ACR Convergence 2023.

Tofacitinib improves enthesitis in patients with psoriatic arthritis regardless of severity or location at baseline, according to data published in Arthritis Research and Therapy.

SAN DIEGO — Izokibep, a novel interleukin-17A inhibitor and nanobody drug, demonstrates “high rates of response” in psoriatic arthritis through 46 weeks, according to a speaker at ACR Convergence 2023.

In patients with psoriatic arthritis and an inadequate response to TNF inhibitors, guselkumab reduces levels of effector cytokines linked to arthritis and skin disease activity, according to data published in Arthritis Research & Therapy.